Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population

Philip E. Castle, Katherine M. Smith, Thomas E. Davis, Kathleen M. Schmeler, Daron Gale Ferris, Ashlyn H. Savage, Jermaine E. Gray, Mark H. Stoler, Thomas C. Wright, Alex Ferenczy, Mark H. Einstein

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives: The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform. Methods: In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA). Results: The κ and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5%, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0% using specimen A and 90.4% using specimen B for Xpert, 90.4% for cobas, and 81.6% for hc2. Conclusions: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.

Original languageEnglish (US)
Pages (from-to)126-133
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume143
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Colposcopy
Referral and Consultation
DNA
Population
Forensic Anthropology
Cervical Intraepithelial Neoplasia

Keywords

  • Microbiology
  • Molecular diagnostics
  • Virology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. / Castle, Philip E.; Smith, Katherine M.; Davis, Thomas E.; Schmeler, Kathleen M.; Ferris, Daron Gale; Savage, Ashlyn H.; Gray, Jermaine E.; Stoler, Mark H.; Wright, Thomas C.; Ferenczy, Alex; Einstein, Mark H.

In: American Journal of Clinical Pathology, Vol. 143, No. 1, 01.01.2015, p. 126-133.

Research output: Contribution to journalArticle

Castle, PE, Smith, KM, Davis, TE, Schmeler, KM, Ferris, DG, Savage, AH, Gray, JE, Stoler, MH, Wright, TC, Ferenczy, A & Einstein, MH 2015, 'Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population', American Journal of Clinical Pathology, vol. 143, no. 1, pp. 126-133. https://doi.org/10.1309/AJCP4Q0NSDHWIZGU
Castle, Philip E. ; Smith, Katherine M. ; Davis, Thomas E. ; Schmeler, Kathleen M. ; Ferris, Daron Gale ; Savage, Ashlyn H. ; Gray, Jermaine E. ; Stoler, Mark H. ; Wright, Thomas C. ; Ferenczy, Alex ; Einstein, Mark H. / Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. In: American Journal of Clinical Pathology. 2015 ; Vol. 143, No. 1. pp. 126-133.
@article{6d5eecbb0afa4b0bbc69983b72ab0ac2,
title = "Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population",
abstract = "Objectives: The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform. Methods: In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA). Results: The κ and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5{\%}, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0{\%} using specimen A and 90.4{\%} using specimen B for Xpert, 90.4{\%} for cobas, and 81.6{\%} for hc2. Conclusions: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.",
keywords = "Microbiology, Molecular diagnostics, Virology",
author = "Castle, {Philip E.} and Smith, {Katherine M.} and Davis, {Thomas E.} and Schmeler, {Kathleen M.} and Ferris, {Daron Gale} and Savage, {Ashlyn H.} and Gray, {Jermaine E.} and Stoler, {Mark H.} and Wright, {Thomas C.} and Alex Ferenczy and Einstein, {Mark H.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1309/AJCP4Q0NSDHWIZGU",
language = "English (US)",
volume = "143",
pages = "126--133",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population

AU - Castle, Philip E.

AU - Smith, Katherine M.

AU - Davis, Thomas E.

AU - Schmeler, Kathleen M.

AU - Ferris, Daron Gale

AU - Savage, Ashlyn H.

AU - Gray, Jermaine E.

AU - Stoler, Mark H.

AU - Wright, Thomas C.

AU - Ferenczy, Alex

AU - Einstein, Mark H.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform. Methods: In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA). Results: The κ and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5%, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0% using specimen A and 90.4% using specimen B for Xpert, 90.4% for cobas, and 81.6% for hc2. Conclusions: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.

AB - Objectives: The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform. Methods: In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA). Results: The κ and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5%, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0% using specimen A and 90.4% using specimen B for Xpert, 90.4% for cobas, and 81.6% for hc2. Conclusions: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.

KW - Microbiology

KW - Molecular diagnostics

KW - Virology

UR - http://www.scopus.com/inward/record.url?scp=84923557905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923557905&partnerID=8YFLogxK

U2 - 10.1309/AJCP4Q0NSDHWIZGU

DO - 10.1309/AJCP4Q0NSDHWIZGU

M3 - Article

C2 - 25511151

AN - SCOPUS:84923557905

VL - 143

SP - 126

EP - 133

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -